Navigation Links
Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
Date:5/29/2013

DALLAS, May 29, 2013 /PRNewswire-iReach/ -- Global Alzheimer's Drugs Market 2012-2016, Alzheimer's Disease Therapeutics and Diagnostics: Global Markets and Alzheimer Disease Treatment Drugs Markets in China are new market research reports available with RnRMarketResearch.com.

(Photo: http://photos.prnewswire.com/prnh/20130529/CG21228)

Global Alzheimer's Drugs market is forecast to grow at a CAGR of 3.26% over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Alzheimer's Drugs market has also been witnessing the availability of improved diagnostics. However, numerous patent expiries could pose a challenge to the growth of this market. Alzheimer's disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients climb and the frustration with lack of effective treatments grows. Though there are a number of marketed drugs approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, there are now numerous companies developing novel treatments.

The report Global Alzheimer's Drugs Market 2012-2016 covers the worldwide Alzheimer's drugs market in the Americas, the EMEA, and the APAC regions, its market landscape, and growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market including but not limited to Eisai Co., Ltd., Forest Laboratories Inc., H. Lundbeck A/S., Novartis AG, and Pfizer Inc. Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=98045.

The scope of the report Alzheimer's Disease Therapeutics and Diagnostics: Global Markets is on the pharmaceutical segment, diagnostics and imaging modalities. It is a compiled study of the market, and current and emerging modes of treatment. The research presents the market segment's economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2012 to 2017. It also projects usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will be of interest also to suppliers of products and services to this market area. The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas. Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=96663.

China's demand for alzheimer disease treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. The new research Alzheimer Disease Treatment Drugs Markets in China examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. Production, demand, sales volume and more for the following have been covered in this report: Ginkgo Bilota Extract, Breviscapine, Ganglioside, Donepezil, Galanthamine, Nicergoline, Rivastigmine, Memantine, Huperzine A,  Oxiracetam, Flunarizine and Piracetam. Buy / Order a copy of this report at 50% discount http://www.rnrmarketresearch.com/contacts/purchase?rname=90552 – listed price is $4000 for a single user license – the same can be availed for US$2000; kindly contact sales@rnrmarketresearch.com with your request for this discounted pricing.

Explore more reports on Alzheimer Drugs and related markets @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/alzheimer-drugs.

About Us:

RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Explore multi-industry reports targeted at geographies across the globe @ http://marketreportsstore.com/. We also have business intelligence and competitive analysis studies focused on multiple industries in China available @ http://www.marketreportschina.com/.

Media Contact:

Priyank Tiwari RnR Market Research, +1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE RnR Market Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
2. New Alzheimers Treatment Protocol Produces Significant Results
3. Ceregene And Alzheimers Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial
4. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
5. NeuroQuest Close to Validation Trial for Biomarker Platform in Diagnosis of Alzheimers
6. New Long-Term Study Suggests Lower Mortality in Alzheimers Patients Treated with Galantamine Versus Placebo
7. Research Published in European Journal of Pharmacology Shows that Star Scientifics Anatabine Suppresses Brain Inflammation in Animal Model of Alzheimers Disease and in Blood
8. Innovative Drugs to Transform European Alzheimers Disease Medication Market by 2015, Says Frost & Sullivan
9. World Alzheimers Report 2012 Reveals Stigma and Social Exclusion are Major Barriers for People With Dementia and Their Carers
10. New International Survey Reveals Multiple Barriers to an Accurate and Timely Alzheimers Disease Diagnosis
11. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Center for ... for caregivers of those affected by autism spectrum disorder (ASD) and other developmental disabilities. ... Seals Maine, will give parents and other caregivers the opportunity to share stories and ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... U.S. Surgeon ... interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at ... learned that medicine is about more than making diagnoses and prescribing medicine,” he states. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... ... 02, 2016 , ... More than half of American teens report losing their ... speaking with their child about sex related topics, less than 60 percent spoke about ... to announce the launch of its second edition of the “Sexual Wellness” campaign, aiming ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, ... through labeling, storing, shipping and disposal. The new version is a faster and ...
Breaking Medicine News(10 mins):